AstraZeneca, Nektar constipation drug wins European approval
LONDON, Dec (Shanghai: 600875.SS - news) 9 (Reuters) - AstraZeneca (NYSE: AZN - news) 's new drug for the treatment of opioid-induced constipation, which was developed with Nektar Therapeutics (NasdaqGS: NKTR - news) , has been approved in the European Union, the British company said on Tuesday.
The approval for Moventig had been expected after the European Medicines Agency gave a green light for the product in September.
The drug was also approved in September in the United States under the brand name Movantik.
(Reporting by Ben Hirschler; Editing by Greg Mahlich)